Infection with HIV associated with increased risk of dialysis and end-stage kidney disease
Dolutegravir shows good efficacy across broad range of patient groups
New tenofovir formulation works equally well with less effect on kidneys and bones
Loss of kidney function in older people with HIV underlines need for earlier treatment
Cleared HCV infection associated with increased risk of kidney disease in people with HIV
Kidney problems linked to tenofovir use, improve with switch to abacavir
New pro-drug tenofovir alafenamide appears equally effective but better tolerated
